Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
All three companies are developing drugs made up of a shortened version of the dystrophin gene, which normally protects muscle cells but is absent in boys with Duchenne.
U.S. Markets open in 4 hrs 16 mins
S&P Futures
2,927.50+6.25(+0.21%)Dow Futures
26,561.00+41.00(+0.15%)Nasdaq Futures
7,624.00+28.75(+0.38%)Russell 2000
1,708.81+3.49(+0.20%)Crude Oil
72.20-0.08(-0.11%)Gold
1,203.80-1.30(-0.11%)Silver
14.51+0.01(+0.08%)EUR/USD
1.180.00(-0.00%)
Pfizer launches Duchenne gene therapy study, joining Sarepta and Solid
American City Business Journals•